Former Pfizer head Kindler joins Lux Capital
pharmafile | August 10, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Kindler, Pfizer
Venture capital firm Lux Capital has appointed former Pfizer chairman and chief executive Jeff Kindler as a partner.
Kindler will help identify new healthcare investment opportunities and work with Lux portfolio companies. He joins other recent venture partner additions Jim Woolsey (former CIA director) and Richard Foster (former McKinsey senior partner) to source breakthrough ventures and entrepreneurs.
Richard Foster, venture partner at Lux Capital said: “Jeff has a strong track record of identifying important emerging trends and capitalising on them commercially – through operational leadership across both science and consumer businesses. We are excited to have Jeff’s insights as a key member of the Lux team.”
“I have great respect for the work Lux Capital is doing to build and back companies addressing some of healthcare’s biggest challenges,” said Kindler.
In addition to his role as venture partner at Lux Capital, Kindler is senior advisor to Paragon Pharmaceuticals, a global investment firm that builds and manages innovative pharmaceutical companies.
He also serves on the boards of AgaMatrix, a developer and manufacturer of diabetes products; Intrexon, a synthetic biology company; Sheridan Healthcare, a provider of healthcare solutions to physicians, hospitals, and outpatient centers; PPD, a global contract drug discovery and development research organization; Tufts University; the National Center on Addiction and Substance Abuse at Columbia University; and the Manhattan Theatre Club.
He is a member of President Obama’s Management Advisory Board and a director at Starboard Capital Partners, a Connecticut-based private equity firm.
Kindler was formerly the chairman and chief executive of Pfizer, the world’s largest research-based biopharmaceutical company, which he joined in January 2002 and from which he retired in December 2010.
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …
